Brazil Gives Medtech More Time to Deal With Technical Dossier Rule
Executive Summary
Anvisa has extended the deadline for companies to prepare technical dossiers for low-risk medical devices and in vitro diagnostics, giving industry more time to deal with the costs and work involved with complying with the new requirement.
You may also be interested in...
Brazil’s ANVISA Globalizes on Class I/II Medtech Regs, Hikes Fees
New medical technology resolutions issued by Brazil’s healthcare products regulatory agency, ANVISA, are designed to help both the regulator and medtech manufacturers, in terms of simplified processes and speed to market.
Moment Of Truth For Seven EU Filings; Cytokinetics To Make Its Case For Heart Failure Drug
The CHMP, the European Medicines Agency’s human medicines committee, will this week decide whether a range of new medicines merit being approved.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.